SynthesisBMC pulmonary medicine2026
Role of systemic corticosteroids in ventilated patients with chronic obstructive pulmonary disease exacerbation: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe recommendation regarding systemic corticosteroids in ventilated patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is unknown since most studies have excluded ventilated patients. Our study aims to investigate whether systemic steroids benefit the subgroup of AECOPD who require ventilation.
methodsWe systematically searched PubMed, Cochrane, and Embase databases for randomized trials or observational studies comparing systemic steroids to placebo or no systemic steroids, up to April 2025. Outcomes of interest were intensive care unit (ICU) mortality, length of ICU stay, duration of ventilation, non-invasive ventilation (NIV) failure rate, hyperglycemia episodes, and ventilator-associated pneumonia (VAP).
resultsSix studies including 1596 ventilated AECOPD patients (including subgroups from larger ICU populations), were included in the systematic review. Of these 1424 contributed to the quantitative synthesis of at least one outcome. We performed sensitivity analysis for study type and mode of ventilation. ICU mortality was not significantly decreased in the systemic steroid group compared to placebo or no systemic steroids (Odds ratio (OR) = 1.09; 95% CI 0.62-1.91; p = 0.78; I²=0.0%). There was no statistically significant difference between the groups for duration of ventilation (Mean difference (MD) = -2.24; 95% CI -5.13 to 0.66; p = 0.13; I²=78.7%). In the subgroup of randomized controlled trials (RCTs), systemic steroids were associated with a shorter duration of ventilation (MD = -1.12 days; 95% CI -2.23 to 0.00; p = 0.049; I² = 59.9%). There was no difference between groups for length of ICU stay (MD = -1.60; 95% CI -3.32 to 0.12; p = 0.068; I²=68.5%). There was no statistically significant difference between groups for NIV failure (Odds ratio (OR) = 1.17; 95% CI 0.83-1.67; p = 0.37; I²=58.1%). Hyperglycemia episodes were significantly higher in the steroid group (OR = 2.38; 95% CI 1.56 to 3.62; p < 0.001; I²=0.0%). There was no significant difference in rates of VAP (OR = 1.19; 95% CI 0.80-1.77; p = 0.38; I²=0.0%).
conclusionThis meta-analysis suggests that critically ill AECOPD patients on ventilation may not derive a significant benefit from systemic steroids. PROSPERO PROTOCOL NO: CRD420251034592.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.